You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Johnson and Johnson
Express Scripts
Dow

Last Updated: August 15, 2020

DrugPatentWatch Database Preview

NYSTATIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Nystatin patents expire, and when can generic versions of Nystatin launch?

Nystatin is a drug marketed by Actavis Mid Atlantic, Cosette, Crown Labs Inc, Fougera Pharms, Perrigo New York, Taro, Torrent, Vintage, Cadila, Lyne, Paddock Llc, Epic Pharma Llc, Lupin, Mayne Pharma Inc, Nesher Pharms, Upsher Smith Labs, Xgen Pharms, Alpharma Us Pharms, Fougera Pharms Inc, G And W Labs Inc, Hi Tech Pharma, Lannett Co Inc, Morton Grove, Pharm Assoc, Pharmaderm, Pharmafair, Socorro, Teva, Vistapharm, Wockhardt Bio Ag, Heritage Pharms Inc, Quantum Pharmics, Sandoz, Sun Pharm Industries, Watson Labs, Fougera, Odyssey Pharms, Amneal Pharms Llc, Dr Reddys, Glenmark Pharms Ltd, Lupin Ltd, Perrigo Uk Finco, Akorn, Rising, Strides Pharma, Teligent Pharma Inc, and Vitruvias Therap. and is included in eighty-three NDAs.

The generic ingredient in NYSTATIN is nystatin; triamcinolone acetonide. There are eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the nystatin; triamcinolone acetonide profile page.

Drug patent expirations by year for NYSTATIN
Drug Prices for NYSTATIN

See drug prices for NYSTATIN

Drug Sales Revenue Trends for NYSTATIN

See drug sales revenues for NYSTATIN

Recent Clinical Trials for NYSTATIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 2
National Cancer Institute (NCI)Phase 2
Medical Research Institute of New ZealandPhase 3

See all NYSTATIN clinical trials

Pharmacology for NYSTATIN
Medical Subject Heading (MeSH) Categories for NYSTATIN

US Patents and Regulatory Information for NYSTATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms Inc NYSTATIN AND TRIAMCINOLONE ACETONIDE nystatin; triamcinolone acetonide OINTMENT;TOPICAL 062602-001 Oct 9, 1985 AT RX No No   Start Trial   Start Trial   Start Trial
Wockhardt Bio Ag NYSTATIN nystatin SUSPENSION;ORAL 062512-001 Oct 29, 1984 AA RX No Yes   Start Trial   Start Trial   Start Trial
Morton Grove NYSTATIN nystatin SUSPENSION;ORAL 062835-001 Nov 19, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Mallinckrodt
Colorcon
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.